Hemodynamic changes caused by glibenclamide in isolated, working, erythrocyte perfused rat heart.

Glibenclamide-induced cardiac hemodynamic changes before and after ischemia have been frequently studied. In general a Langendorff buffer perfused heart model was used to examine these effects. However these models used protein-free buffer perfusates. To improve clinical relevance and thereby enhance extrapolation to the in vivo condition we studied the effects of glibenclamide on cardiac hemodynamics using a working, erythrocyte perfused, rat heart model, where the perfusate was enriched with albumin. The results show a dose-dependent decline in CBF in normoxia and at the end of reperfusion (after an ischemic period) with glibenclamide treatment compared to control. Cardiac functional recovery improved with 1 and 4 mumol.L-1 glibenclamide concentrations. From this study it seems that there is a marked decrease in CBF but this did not result in impaired myocardial function after a period of ischemia, so it appears that there are no startling side effects of glibenclamide in the ischemic rat heart.
AuthorsR J Legtenberg, R J Houston, P Smits, B Oeseburg
JournalAdvances in experimental medicine and biology (Adv Exp Med Biol) Vol. 471 Pg. 257-63 ( 1999) ISSN: 0065-2598 [Print] UNITED STATES
PMID10659155 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hypoglycemic Agents
  • Potassium Channel Blockers
  • Glyburide
  • Animals
  • Coronary Vessels (drug effects, physiopathology)
  • Erythrocytes
  • Glyburide (pharmacology)
  • Heart (drug effects, physiopathology)
  • Hemodynamics (drug effects)
  • Hypoglycemic Agents (pharmacology)
  • Male
  • Potassium Channel Blockers
  • Rats
  • Rats, Wistar

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: